Transaction values Ignite Proteomics at approximately $150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as a separate Nasdaq-listed...
Registry expected to pair Ignite’s reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for Ignite...
Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders...
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of...
Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite’s platform — the only commercially available multiplex assay in the study—demonstrates predictive...
Busch brings public company leadership and capital markets experience to support Ignite’s next phase of growth
Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options.
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its...
Aditxt has filed a preliminary proxy statement seeking shareholder approval for employee stock purchase plan, company name change, and other proposals
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of...